Micardis
(Telmisartan)ApprovedSmall molecule
Boehringer IngelheimTelmisartan is used to treat high blood pressure and to help prevent heart problems in people at high risk. It works by relaxing blood vessels so blood can flow more easily through your body.[2] Micardis is currently approved and in use across 46 indications[4].[1]
Micardis is one of 981 small molecule programs targeting Insulin resistance. It is currently in Approved.
46
Indications
156
Total Trials
5
Active Trials
980
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 45 indications
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Micardis
Boehringer IngelheimApproved
Biaxin
AbbViePreclinical
Singulair
AstraZenecaPreclinical
Nexavar
BayerPreclinical
Nitrostat
VViatris Specialty LLC
Preclinical
Aquasol E
NNational Eye Institute (NEI)
Preclinical
Tricor
JJagotec
Preclinical
Low-Molecular-Weight Heparin
Daiichi SankyoPreclinical
Statin
Bristol-Myers SquibbPreclinical
Antihypertensive Agents
NNational Heart, Lung, and Blood Institute (NHLBI)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hypertension24 trials
Show 21 more trials
Hypertensive14 trials
Replication of the TRANSCEND Antihypertensive Trial in Healthcare Claims Data
Completed·—··NCT04354376·40,048 enrolled
Replication of the ONTARGET Antihypertensive Trial in Healthcare Claims Data
Completed·—··NCT04354350·63,744 enrolled
Show 11 more trials
ART14 trials
Show 11 more trials
Comparative Study of the Effects of Telmisartan and Nebivolol
Unknown status·—·Phase 4·NCT02057328·80 enrolled
Essential Hypertension10 trials
Show 7 more trials
Female7 trials
Show 4 more trials
58 more indications
Interaction6 trials
Efficacy and Safety4 trials
Trial4 trials
Metabolic Syndrome4 trials
The Effects of Peroxisome Proliferators Activated Receptor-Gamma (PPAR-γ) Agonists on Certain Biochemical and Inflammatory Markers in Metabolic Syndrome
Completed·—·Phase 4·NCT00926341·110 enrolled
COVID-194 trials
Hyperlipidemia3 trials
Cardiovascular2 trials
Heart Failure2 trials
Polycystic Kidney Disease2 trials
HALT Progression of Polycystic Kidney Disease Study A
Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 3·NCT00283686·558 enrolled
HALT Progression of Polycystic Kidney Disease Study B
Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 3·NCT01885559·486 enrolled
Nephropathy2 trials
Diabetes2 trials
Blood Pressure2 trials
Tics2 trials
Oral2 trials
Peripheral Artery Disease1 trial
AIDS1 trial
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 2·NCT01928927·58 enrolled
Atrial Fibrillation1 trial
Nifedipine vs Telmisartan on Prevention of Atrial Fibrillation (AF) Recurrence in Hypertensive Patients With AF
Completed·TThe Second Affiliated Hospital of Chongqing Medical University·Phase 4·NCT01435161·160 enrolled
Adult1 trial
Safety and Efficacy1 trial
Efficacy1 trial
Bicuspid aortic valve1 trial
HIV1 trial
Parkinson's Disease1 trial
Schizophrenia1 trial
Atorvastatin1 trial
Double-blind1 trial
Endothelial Dysfunction1 trial
Type 2 Diabetes Mellitus1 trial
Cardiovascular Events1 trial
Acute Coronary Syndrome1 trial
Telmisartan Versus Ramipril After Acute Coronary Syndrome
Unknown status·—·Phase 4·NCT00702936·50 enrolled
Cardiotoxicity1 trial
Allogeneic Hematopoietic Stem Cell Transplantation1 trial
Abdominal Aortic Aneurysm1 trial
Statin1 trial
Clopidogrel1 trial
Hypercholesterolemia1 trial
HIV infection1 trial
Ovarian Cancer1 trial
Alcoholic Fatty Liver Disease1 trial
Coronary Artery Disease1 trial
SARS CoV 2 Infection1 trial
Diabetic Nephropathy1 trial
Neuropathic Pain1 trial
Prevention of Paclitaxel-induced Neuropathic Pain in Patients With Planned Paclitaxel Chemotherapy (PrevTel)
Completed·—·Phase 2·NCT05322889·35 enrolled
Chronic Kidney Disease1 trial
Complication1 trial
Regulatory
FDA Approval Timeline[5]
Apr 4, 2000
MICARDIS
NDA NDA020850
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Micardis drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Telmisartan. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Type-1 Angiotensin II Receptor Antagonist[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company